Compare OI & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OI | NRIX |
|---|---|---|
| Founded | 1903 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Containers/Packaging | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | N/A | 2020 |
| Metric | OI | NRIX |
|---|---|---|
| Price | $14.97 | $19.36 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 13 |
| Target Price | $16.29 | ★ $27.46 |
| AVG Volume (30 Days) | ★ 2.5M | 1.9M |
| Earning Date | 02-03-2026 | 01-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $6,455,000,000.00 | $83,687,000.00 |
| Revenue This Year | $1.41 | $59.40 |
| Revenue Next Year | $1.99 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 48.32 |
| 52 Week Low | $9.23 | $8.18 |
| 52 Week High | $16.04 | $22.50 |
| Indicator | OI | NRIX |
|---|---|---|
| Relative Strength Index (RSI) | 61.91 | 63.80 |
| Support Level | $14.47 | $17.44 |
| Resistance Level | $15.34 | $19.67 |
| Average True Range (ATR) | 0.43 | 1.14 |
| MACD | -0.04 | -0.20 |
| Stochastic Oscillator | 58.33 | 37.95 |
O-I Glass is the world's largest manufacturer of glass bottles; 70% of its revenue comes from outside the United States. O-I has a leading position in key markets such as Europe, North America, and Brazil. Beer is the primary end market for O-I's glass bottles, which are also used for wine, soda, spirits, condiments, and food. O-I is looking to maintain or expand its dominant positions in Europe, North America, and South America.
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.